Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FXX489 (NNS309) PET/CT Imaging in Tumor Diagnosis
NCT07144085Phase 1Recruiting
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-FXX489 in tumor and metastatic cancer. Primary endpoints: Count of participants with treatment-emergent adverse events up to 3 days, Proportion of radiation-absorbed doses of radiolabeled FAP-2286 up to 3 days and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
68Ga-FXX489
03
Conditions
tumormetastatic cancer
Beyond the preview
Go deeper on NCT07144085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144085.